Free Trial
NYSE:ZTS

Zoetis (ZTS) Stock Price, News & Analysis

$170.89
-1.16 (-0.67%)
(As of 05/23/2024 ET)
Today's Range
$169.73
$172.49
50-Day Range
$145.54
$174.47
52-Week Range
$144.80
$201.92
Volume
1.94 million shs
Average Volume
3.08 million shs
Market Capitalization
$77.98 billion
P/E Ratio
32.93
Dividend Yield
1.01%
Price Target
$211.75

Zoetis MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
23.9% Upside
$211.75 Price Target
Short Interest
Healthy
1.13% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-4.66
Upright™ Environmental Score
News Sentiment
0.71mentions of Zoetis in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$299,514 Sold Last Quarter
Proj. Earnings Growth
9.88%
From $5.77 to $6.34 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.69 out of 5 stars

Medical Sector

63rd out of 915 stocks

Pharmaceutical Preparations Industry

18th out of 399 stocks

ZTS stock logo

About Zoetis Stock (NYSE:ZTS)

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

ZTS Stock Price History

ZTS Stock News Headlines

Zoetis declares $0.432 dividend
Zoetis Declares Third Quarter 2024 Dividend
Zoetis: Long-Term Buy Despite Safety Concerns
Q1 2024 Zoetis Inc Earnings Call
Zoetis: Q1 Earnings Snapshot
Zoetis Inc. Q1 Profit Increases, beats estimates
Zoetis Earnings Top; Pet Drugmaker Rises
See More Headlines
Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 3/1 Dividend
1/18/2024
Dividend Payable
3/01/2024
Ex-Dividend for 6/4 Dividend
4/18/2024
Last Earnings
5/02/2024
Today
5/23/2024
Dividend Payable
6/04/2024
Next Earnings (Estimated)
8/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
98978V10
Employees
14,100
Year Founded
2012

Price Target and Rating

Average Stock Price Target
$211.75
High Stock Price Target
$237.00
Low Stock Price Target
$180.00
Potential Upside/Downside
+23.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$2.34 billion
Pretax Margin
34.19%

Debt

Sales & Book Value

Annual Sales
$8.54 billion
Cash Flow
$6.35 per share
Book Value
$11.07 per share

Miscellaneous

Free Float
455,565,000
Market Cap
$77.98 billion
Optionable
Optionable
Beta
0.86

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives


ZTS Stock Analysis - Frequently Asked Questions

Should I buy or sell Zoetis stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZTS shares.
View ZTS analyst ratings
or view top-rated stocks.

What is Zoetis' stock price target for 2024?

7 brokers have issued 12 month target prices for Zoetis' shares. Their ZTS share price targets range from $180.00 to $237.00. On average, they anticipate the company's share price to reach $211.75 in the next twelve months. This suggests a possible upside of 23.9% from the stock's current price.
View analysts price targets for ZTS
or view top-rated stocks among Wall Street analysts.

How have ZTS shares performed in 2024?

Zoetis' stock was trading at $197.37 at the beginning of 2024. Since then, ZTS shares have decreased by 13.4% and is now trading at $170.89.
View the best growth stocks for 2024 here
.

Are investors shorting Zoetis?

Zoetis saw a increase in short interest in April. As of April 30th, there was short interest totaling 5,170,000 shares, an increase of 62.6% from the April 15th total of 3,180,000 shares. Based on an average daily volume of 3,690,000 shares, the days-to-cover ratio is currently 1.4 days. Currently, 1.1% of the shares of the stock are sold short.
View Zoetis' Short Interest
.

When is Zoetis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our ZTS earnings forecast
.

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) released its quarterly earnings results on Thursday, May, 2nd. The company reported $1.38 EPS for the quarter, beating the consensus estimate of $1.34 by $0.04. The firm earned $2.19 billion during the quarter, compared to analysts' expectations of $2.14 billion. Zoetis had a trailing twelve-month return on equity of 50.34% and a net margin of 27.38%. The business's revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter last year, the business earned $1.31 earnings per share.
Read the conference call transcript
.

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis announced a quarterly dividend on Tuesday, February 6th. Investors of record on Friday, April 19th will be given a dividend of $0.432 per share on Tuesday, June 4th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.01%. The ex-dividend date is Thursday, April 18th.
Read our dividend analysis for ZTS
.

Is Zoetis a good dividend stock?

Zoetis (NYSE:ZTS) pays an annual dividend of $1.73 per share and currently has a dividend yield of 1.00%. The company has been increasing its dividend for 13 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 33.33%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ZTS will have a dividend payout ratio of 27.29% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ZTS.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis issued an update on its FY 2024 earnings guidance on Friday, May, 3rd. The company provided EPS guidance of 5.710-5.810 for the period, compared to the consensus EPS estimate of 5.790. The company issued revenue guidance of $9.1 billion-$9.2 billion, compared to the consensus revenue estimate of $9.2 billion.

What is Kristin Peck's approval rating as Zoetis' CEO?

50 employees have rated Zoetis Chief Executive Officer Kristin Peck on Glassdoor.com. Kristin Peck has an approval rating of 82% among the company's employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.

What other stocks do shareholders of Zoetis own?
Who are Zoetis' major shareholders?

Zoetis' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.93%), Price T Rowe Associates Inc. MD (2.05%), Capital World Investors (1.38%), Bank of New York Mellon Corp (0.99%), Capital Research Global Investors (0.89%) and Clearbridge Investments LLC (0.63%). Insiders that own company stock include Glenn David, Gregory Norden, Heidi C Chen, Kristin C Peck, Robert J Polzer, Roman Trawicki, Roxanne Lagano and Willie M Reed.
View institutional ownership trends
.

How do I buy shares of Zoetis?

Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Zoetis have any subsidiaries?
The following companies are subsidiares of Zoetis: Abaxis, Abaxis Asia Limited, Abaxis Europe GmbH, Abaxis Inc., Abaxis South East Europe d. o.o., Abaxis UK Limited, Alpharma Animal Health Company, Alpharma Animal Health Hong Kong Co. Limited, Alpharma Bermuda LLC, Alpharma Euro Holdings LLC, Alpharma Holdings Barbados SRL, Alpharma LLC, Alpharma Luxembourg S.A.R.L. y Compania Limitada, Alpharma do Brasil Ltda., Bovigen, Catapult Genetics Pty Ltd, Continental Farmaceutica SPRL, Cross Vetpharm Group Limited, Embrex LLC, Ethos Diagnostic Science, Fish Vet Group, Fish Vet Group Limited, Jilin Zoetis Guoyuan Animal Health Co. Ltd., Jorox Pty, King Animal Health, Microtek International Inc, Mikjan Corporation, Nexvet, Nexvet Australia Pty Ltd, PAH 7V6 Holding Limited, PAH CHHK Holding B.V., PAH India Holdco LLC, PAH India Holding 1 B.V., PAH Netherlands 2 B.V., PAH Oceania B.V., PAH Spain S.L., PHARMAQ, PT Zoetis Animalhealth Indonesia, Performance Livestock Analytics, Performance Livestock Analytics Inc., Pharmaq AS Chile Limitada, Pharmaq AS Service SpA, Pharmaq AS., Pharmaq Analytiq AS, Pharmaq Analytiq Limited, Pharmaq Analytiq SpA, Pharmaq Fishteq AS, Pharmaq Fishteq SpA, Pharmaq Ltd, Pharmaq Spain Aqua SL, Pharmaq Veterinar Ecza Deposu ve su Urunleri Ticaret Ltd Ski, Pharmaq Vietnam Company Limited, Phoenix Central Laboratory for Veterinarians Inc., Phoenix Lab, Platinum Performance, Platinum Performance Inc., Pumpkin Holdings Inc., Pumpkin Insurance Services Inc., Scandinavian Micro Biodevices, Smartbow GmbH, Smartbow RUS OOO, Synbiotics Corporation, Synbiotics LLC, Vetnex Animal Health Ltd, Virtual Recall, Virtual Recall Limited, Virtual Recall Pty Ltd, ZNLabs, ZNLabs LLC, ZOETISECUADOR Cia. Ltda., Zoetis Animal Health ApS, Zoetis Argentina S.R.L., Zoetis Australia Pty Ltd, Zoetis Australia Research & Manufacturing Pty Ltd, Zoetis B.V., Zoetis Belgium S.A., Zoetis Biopharmaceutical Co. Ltd, Zoetis Broomhill IP Limited, Zoetis Broomhill Property Limited, Zoetis C.A., Zoetis Canada Inc., Zoetis Colombia S.A.S., Zoetis Costa Rica S.R.L., Zoetis Denmark ApS, Zoetis Deutschland GmbH, Zoetis Egypt LLC, Zoetis Egypt Pharmaceuticals LLC, Zoetis Egypt Trading LLC, Zoetis Enterprise Management Shanghai Co. Ltd., Zoetis Finland Oy, Zoetis France, Zoetis Hayvan Sagligi Ltd. Sti., Zoetis Hellas S.A., Zoetis Holdings LLC, Zoetis Hungary Kft., Zoetis Import Egypt LLC, Zoetis India Limited, Zoetis Indústria de Produtos Veterinários Ltda., Zoetis International Holdings B.V., Zoetis Israël Holding B.V., Zoetis Italia S.r.l., Zoetis Japan K.K., Zoetis Korea Ltd., Zoetis LLC, Zoetis Luxembourg Holding S.à r.l., Zoetis Malaysia Sdn. Bhd., Zoetis Manufacturing & Research Spain S.L., Zoetis Manufacturing Italia S.R.L., Zoetis Medolla Manufacturing S.R.L., Zoetis Mexico S. de R.L. de C.V., Zoetis Netherlands 1 B.V., Zoetis Netherlands 3 B.V., Zoetis Netherlands 4 B.V., Zoetis Netherlands 5 B.V., Zoetis New Zealand Limited, Zoetis OOO, Zoetis Overseas Holding B.V., Zoetis Overseas Services Inc., Zoetis Panama S. de R.L., Zoetis Pharmaceutical Research Private Limited, Zoetis Philippines Inc., Zoetis Polska sp. z o.o, Zoetis Portugal Lda., Zoetis Products Inc., Zoetis Reference Laboratories China Co. Ltd., Zoetis Reference Labs LLC, Zoetis Romania SRL, Zoetis S.R.L., Zoetis Salud Animal de Bolivia S.A., Zoetis Schweiz GmbH, Zoetis Services LLC, Zoetis Singapore Pte. Ltd., Zoetis South Africa Pty Ltd., Zoetis Spain S.L., Zoetis Subsidiary Holdings Inc., Zoetis Suzhou Manufacturing Co. Ltd., Zoetis Sweden AB, Zoetis Taiwan Limited, Zoetis Thailand Limited, Zoetis Treasury Center BV, Zoetis UK Limited, Zoetis US LLC, Zoetis Ukraine LLC, Zoetis Vietnam Limited Liability Company, Zoetis WLC LLC, Zoetis Weesp B.V., Zoetis Yantai Manufacturing Co. Ltd., Zoetis de Chile S.A., Zoetis de Uruguay S.R.L., Zoetis Österreich GmbH, and Zoetis Česká republika s.r.o..
Read More
This page (NYSE:ZTS) was last updated on 5/24/2024 by MarketBeat.com Staff

From Our Partners